WeightWatchers and GLP-1 drugs: a new combo for weight loss?

NCT ID NCT06034457

Completed Disease control Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a 24-week program that combines WeightWatchers behavioral coaching with prescription GLP-1 medications like Wegovy, Mounjaro, or Zepbound. 180 adults with obesity or weight-related conditions participated. Researchers measured weight loss and related outcomes at 12 and 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 medications (Wegovy, Mounjaro, or Zepbound)
What this could lead to: If successful, this program could offer a structured way to achieve significant weight loss using GLP-1 drugs alongside behavioral support.
What could go wrong: This was a small, single-arm study without a comparison group, so results may not be generalizable. GLP-1 medications can cause side effects like nausea and require ongoing use to maintain weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY WEIGHT LOSS

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.